Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul;25(3):214-20.
doi: 10.3802/jgo.2014.25.3.214. Epub 2014 Jul 3.

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia

Weiwei Shan  1 , Chao Wang  2 , Zhenbo Zhang  3 , Chao Gu  1 , Chengcheng Ning  4 , Xuezhen Luo  4 , Qiongjie Zhou  4 , Xiaojun Chen  4
Affiliations
Randomized Controlled Trial

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia

Weiwei Shan et al. J Gynecol Oncol. 2014 Jul.

Abstract

Objective: To compare the efficacy of metformin plus megestrol acetate (MA) with that of MA alone for treating endometrial atypical hyperplasia (EAH).

Methods: This pilot study included 16 EAH patients who met at least one metabolic syndrome (MS) criterion and received either adjunctive metformin plus MA (MET group) or MA monotherapy (MA group). Each patient in the MA group received 160 mg of MA daily, whereas patients in the MET group received the same dose of MA plus 0.5 g of metformin thrice daily. Treatment response was assessed by histological examination of dilation and curettage specimens obtained after 12 weeks of therapy.

Results: Each group had eight patients, and half of the patients in each group were diagnosed with MS. The complete response (CR) rate was 75% (6/8) in the MET group and 25% (2/8) in the MA group (p=0.105). Complications of MS did not affect the response rates in either group. In the MET group, 75% (3/4) of the patients had CR in the presence or absence of MS. In the MA group, 50% (2/4) of the patients with MS had CR, whereas no patient without MS had CR. No irreversible toxicities were observed.

Conclusion: Metformin plus MA may be a potential alternative therapy for treating EAH, and the MS status of patients may have no effect on the efficacy of metformin plus MA therapy.

Keywords: Endometrial hyperplasia; Megestrol acetate; Metformin.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Study design. CR, complete response; MA, megestrol acetate; MET, metformin plus MA; NR, no response; PR, partial response.
Fig. 2
Fig. 2
Response distribution in the megestrol acetate (MA) and metformin plus MA (MET) groups in the study. Response distribution was compared between the two groups (p=0.105). CR, complete response; NR, no response; PR, partial response.
Fig. 3
Fig. 3
Response distribution in the presence and absence of metabolic syndrome (MS) in the megestrol acetate (MA) and metformin plus MA (MET) groups. (A) It shows the response rates of the patients who did not meet the MS criteria in the two groups. Response distribution in the absence of MS was compared between the two groups (p=0.127). (B) It shows the response rates of the patients who met the MS criteria in the two groups. Response distribution in the presence of MS was compared between the two groups (p=0.495). CR, complete response; NR, no response; PR, partial response.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125:263–270. - PubMed
    1. Nucera G, Mandato VD, Gelli MC, Palomba S, La Sala GB. Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report. Gynecol Endocrinol. 2013;29:219–221. - PubMed
    1. Brown AJ, Westin SN, Broaddus RR, Schmeler K. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol. 2012;119(2 Pt 2):423–426. - PMC - PubMed
    1. Jasonni VM, Franceschetti F, Ciotti P, Bulletti C, Vignudelli A, Marabini A, et al. Treatment of endometrial hyperplasia with cyproterone acetate histological and hormonal aspects. Acta Obstet Gynecol Scand. 1986;65:685–687. - PubMed
    1. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798–2803. - PubMed

Publication types

MeSH terms